Our experts guide you through all aspects of non-clinical development from lead candidate selection to market approval.
Together we cover a broad range of indications and therapies, ranging from small molecules, vaccines and biotechnology-derived products to novel therapies such as oligonucleotides and advanced therapy medicinal products (ATMPs) including gene therapy, cell therapy and tissue engineering products.
Our global network consists of a broad spectrum of KOLs, research institutes and contract research organizations (CROs) with whom we collaborate(d) in the past and present. As we operate totally independent and unbiased, we can efficiently support the CRO selection process to make sure we identified the best partner to execute your non-clinical efficacy and safety studies.
Besides working with you to ensure that all studies are conducted in compliance with all necessary regulations, we can help you compile the necessary non-clinical input in the preparation of regulatory documentation such as an IB, CTA/IND, Briefing Book and MAA/CTD.
As our experts have experience in a broad range of indications and therapies, we can support the decision-making process and help you to identify critical next steps.